DKSH partners with R-Biomeds to bring oncology and thyroid treatments to Cambodia

DKSH Healthcare, a leading partner for healthcare companies seeking to expand their business in Asia and beyond, has signed an exclusive agreement with R-Biomeds, a global pharmaceutical company headquartered in Singapore.

As part of the collaboration, DKSH will expand R-Biomeds’ range of medicines, including oncology, biosimilars and thyroid medicines, into the Cambodian market.
As a strategic partner, DKSH has been working with R-Biomeds to drive its growth in Myanmar with great success and is now expanding its partnership in Cambodia. DKSH Cambodia will help R-Biomeds grow its business, strengthen its brand presence and gain market share by managing its distribution and logistics, marketing and sales. Its experienced team and extensive distribution network will ensure that its products reach modern and traditional trade, hospitals, clinics, other healthcare channels and patients in need across the country.

Rajeev Rawal, Managing Director of R-Biomeds, said: "We are delighted to partner with DKSH to provide our high-quality medicines to Cambodian patients. We believe that DKSH's strong national presence, extensive distribution network and expertise will further strengthen R-Biomeds' brand and growth in this market."

Philip Wray, Vice President of Healthcare Cambodia at DKSH, said: "With our expertise in market expansion services, we are proud to be a trusted strategic partner of R-Biomeds. Our collaboration demonstrates our commitment to providing patients with better health and quality of life, which is in line with DKSH's purpose of enriching people's lives and its mission of universal healthcare."